glp-1 agonists and pancreatitis Risk of pancreatic cancer associated with receptor agonist therapy New data links GLP-1 agonists

McCluskey G, Doherty-Allan R, McCarron P, et al

The product type segment includes semaglutide, liraglutide, exenatide, dulaglutide, and others, with semaglutide leading the market in 2024, accounting for 58.4% of total share

However, a small percentage of cases are familial, resulting from mutations in specific genes [82]

What Studies Show Early research suggests that CagriSema may help patients lose even more weight than semaglutide alone

NAFLD can be subdivided according to the level of inflammation ranging from simple steatosis without inflammation to non-alcoholic steatohepatitis (NASH), which is often associated with fibrosis and over time may lead to cirrhosis and end-stage liver failure

Accompanying the increase in use of these drugs has been a surge in individuals seeking guidance regarding their side effects, as well as accidental overdoses